Joost Willemse

Joost Willemse

Auto-generated profile, based on publicly available information

Joost Willemse

Leiden University Institute of Biology

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NBNed P. Buijs
Ned P. Buijs
HVHalana C. Vlaming
Halana C. Vlaming
IKIoli Kotsogianni
Ioli Kotsogianni
MAMelina Arts
Melina Arts
JWJoost Willemse
Joost Willemse
NMNathaniel I. Martin
Nathaniel I. Martin
Bacitracin is a macrocyclic peptide antibiotic that is widely used as a topical treatment for infections caused by gram-positive bacteria. Mechanistically, bacitracin targets bacteria by specifically binding to the phospholipid undecaprenyl pyrophosphate (C 55 PP), which plays a key role in the bacterial lipid II cycle. Recent crystallographic studies have shown that when bound to C 55 PP, bacitracin adopts a highly ordered amphipathic conformation. In doing so, all hydrophobic side chains align on one face of the bacitracin–C 55 PP complex, presumably interacting with the bacterial cell membrane. These insights led us to undertake structure–activity investigations into the individual contribution of the nonpolar amino acids found in bacitracin. To achieve this we designed, synthesized, and evaluated a series of bacitracin analogues, a number of which were found to exhibit significantly enhanced antibacterial activity against clinically relevant, drug-resistant pathogens. As for the natural product, these next-generation bacitracins were found to form stable complexes with C 55 PP. The structure–activity insights thus obtained serve to inform the design of C 55 PP-targeting antibiotics, a key and underexploited antibacterial strategy.

19 June 2024 in Nature Chemistry
Verified
Journal Article
Open access
PDF file
ABAlexander T. Bakker
Alexander T. Bakker
IKIoli Kotsogianni
Ioli Kotsogianni
MAMariana Avalos
Mariana Avalos
JPJeroen M. Punt
Jeroen M. Punt
BLBing Liu
Bing Liu
MSMario van der Stelt
Mario van der Stelt
Bacteria have evolved resistance to nearly all known antibacterials, emphasizing the need to identify antibiotics that operate via novel mechanisms. Here we report a class of allosteric inhibitors of DNA gyrase with antibacterial activity against fluoroquinolone-resistant clinical isolates of Escherichia coli. Screening of a small-molecule library revealed an initial isoquinoline sulfonamide hit, which was optimized via medicinal chemistry efforts to afford the more potent antibacterial LEI-800. Target identification studies, including whole-genome sequencing of in vitro selected mutants with resistance to isoquinoline sulfonamides, unanimously pointed to the DNA gyrase complex, an essential bacterial topoisomerase and an established antibacterial target. Using single-particle cryogenic electron microscopy, we determined the structure of the gyrase–LEI-800–DNA complex. The compound occupies an allosteric, hydrophobic pocket in the GyrA subunit and has a mode of action that is distinct from the clinically used fluoroquinolones or any other gyrase inhibitor reported to date. LEI-800 provides a chemotype suitable for development to counter the increasingly widespread bacterial resistance to fluoroquinolones.

7 August 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
EGEmma van Groesen
Emma van Groesen
EMElma Mons
Elma Mons
IKIoli Kotsogianni
Ioli Kotsogianni
MAMelina Arts
Melina Arts
KTKamaleddin H. M. E. Tehrani
Kamaleddin H. M. E. Tehrani
NMNathaniel I. Martin
Nathaniel I. Martin
Gram-positive bacterial infections present a major clinical challenge, with methicillin- and vancomycin-resistant strains continuing to be a cause for concern. In recent years, semisynthetic vancomycin derivatives have been developed to overcome this problem as exemplified by the clinically used telavancin, which exhibits increased antibacterial potency but has also raised toxicity concerns. Thus, glycopeptide antibiotics with enhanced antibacterial activities and improved safety profiles are still necessary. We describe the development of a class of highly potent semisynthetic glycopeptide antibiotics, the guanidino lipoglycopeptides, which contain a positively charged guanidino moiety bearing a variable lipid group. These glycopeptides exhibited enhanced in vitro activity against a panel of Gram-positive bacteria including clinically relevant methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant strains, showed minimal toxicity toward eukaryotic cells, and had a low propensity for resistance selection. Mechanistically, guanidino lipoglycopeptides engaged with bacterial cell wall precursor lipid II with a higher binding affinity than vancomycin. Binding to both wild-type d -Ala- d -Ala lipid II and the vancomycin-resistant d -Ala- d -Lac variant was confirmed, providing insight into the enhanced activity of guanidino lipoglycopeptides against vancomycin-resistant isolates. The in vivo efficacy of guanidino lipoglycopeptide EVG7 was evaluated in a S. aureus murine thigh infection model and a 7-day sepsis survival study, both of which demonstrated superiority to vancomycin. Moreover, the minimal to mild kidney effects at supratherapeutic doses of EVG7 indicate an improved therapeutic safety profile compared with vancomycin. These findings position guanidino lipoglycopeptides as candidates for further development as antibacterial agents for the treatment of clinically relevant multidrug-resistant Gram-positive infections.

12 June 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
JVJo-Anne Verschoor
Jo-Anne Verschoor
MCMartijn R. J. Croese
Martijn R. J. Croese
SLSven E. Lakemeier
Sven E. Lakemeier
AMAnnemiek Mugge
Annemiek Mugge
CBCharlotte M. C. Burgers
Charlotte M. C. Burgers
Han de WindeHan de Winde
Han de Winde
The rising use of plastic results in an appalling amount of waste which is scattered into the environment. One of these plastics is PET which is mainly used for bottles. We have identified and characterized an esterase from Streptomyces, annotated as LipA, which can efficiently degrade the PET-derived oligomer BHET. The Streptomyces coelicolorScLipA enzyme exhibits varying sequence similarity to several BHETase/PETase enzymes, including IsPETase, TfCut2, LCC, PET40 and PET46. Of 96 Streptomyces strains, 18% were able to degrade BHET via one of three variants of LipA, named ScLipA, S2LipA and S92LipA. SclipA was deleted from S. coelicolor resulting in reduced BHET degradation. Overexpression of all LipA variants significantly enhanced BHET degradation. All variants were expressed in E. coli for purification and biochemical analysis. The optimum conditions were determined as pH 7 and 25 °C for all variants. The activity on BHET and amorphous PET film was investigated. S2LipA efficiently degraded BHET and caused roughening and indents on the surface of PET films, comparable to the activity of previously described TfCut2 under the same conditions. The abundance of the S2LipA variant in Streptomyces suggests an environmental advantage towards the degradation of more polar substrates including these polluting plastics.

9 May 2024 in Environment International
Verified
Journal Article
Open access
MWMeiru Wang
Meiru Wang
SCShuhao Chen
Shuhao Chen
SCShixiong Cheng
Shixiong Cheng
TNTom A.P. Nederstigt
Tom A.P. Nederstigt
Robert PoelmannRobert Poelmann
Robert Poelmann
michael richardsonmichael richardson
michael richardson
Nanoplastics can cause severe malformations in chicken embryos. To improve our understanding of the toxicity of nanoplastics to embryos, we have studied their biodistribution in living chicken embryos. We injected the embryos in the vitelline vein at stages 18-19. We injected polystyrene nanoparticles (PS-NPs) tagged with europium- or fluorescence. Their biodistribution was tracked using inductively-coupled plasma mass spectrometry on tissue lysates, paraffin histology, and vibratome sections analysed by machine learning algorithms. PS-NPs were found at high levels in the heart, liver and kidneys. Furthermore, PS-NPs crossed the endocardium of the heart at sites of epithelial-mesenchymal transformation; they also crossed the liver endothelium. Finally, we detected PS-NPs in the allantoic fluid, consistent with their being excreted by the kidneys. Our study shows the power of the chicken embryo model for analysing the biodistribution of nanoplastics in embryos. Such experiments are difficult or impossible in mammalian embryos. These findings are a major advance in our understanding of the biodistribution and tissue-specific accumulation of PS-NPs in developing animals.

17 July 2023 in Scientific Data
Verified
Journal Article
Open access
PDF file
RHRohola Hosseini
Rohola Hosseini
MVMatthijs Vlasveld
Matthijs Vlasveld
JWJoost Willemse
Joost Willemse
BWBob van de Water
Bob van de Water
SDSylvia Emmanuelle Le Dévédec
Sylvia Emmanuelle Le Dévédec
KWKatherine J. Wolstencroft
Katherine J. Wolstencroft
The Minimum Information for High Content Screening Microscopy Experiments (MIHCSME) is a metadata model and reusable tabular template for sharing and integrating high content imaging data. It has been developed by combining the ISA (Investigations, Studies, Assays) metadata standard with a semantically enriched instantiation of REMBI (Recommended Metadata for Biological Images). The tabular template provides an easy-to-use practical implementation of REMBI, specifically for High Content Screening (HCS) data. In addition, ISA compliance enables broader integration with other types of experimental data, paving the way for visual omics and multi-Omics integration. We show the utility of MIHCSME for HCS data using multiple examples from the Leiden FAIR Cell Observatory, a Euro-Bioimaging flagship node for high content screening and the pilot node for implementing Findable, Accessible, Interoperable and Reusable (FAIR) bioimaging data throughout the Netherlands Bioimaging network.